Match!
Kashif M. Munir
University of Maryland, Baltimore
EndocrinologyType 2 diabetesGlycemicDiabetes mellitusMedicine
34Publications
8H-index
232Citations
What is this?
Publications 35
Newest
#1Peng Cc (University of Maryland Medical Center)
#1Carol Chiung-Hui Peng (University of Maryland Medical Center)H-Index: 1
Last. Kashif M. Munir (UMB: University of Maryland, Baltimore)H-Index: 8
view all 5 authors...
Source
#1Carol Chiung-Hui Peng (University of Maryland Medical Center)H-Index: 1
Last. Pennant M (UMB: University of Maryland, Baltimore)
view all 5 authors...
ABSTRACT Objective Painful Hashimoto's thyroiditis, is a rare Hashimoto's thyroiditis variant characterized by neck pain. The clinical differentiation between painful Hashimoto's thyroiditis and su...
Source
#1Termeh M. Feinberg (Yale University)H-Index: 3
#2L. Susan Wieland (UMB: University of Maryland, Baltimore)H-Index: 12
Last. Christopher R. D'Adamo (UMB: University of Maryland, Baltimore)H-Index: 11
view all 10 authors...
Prediabetes describes a state of hyperglycemia outside of normal limits that does not meet the criteria for diabetes diagnosis, is generally symptomless, and affects an estimated 38% of adults in the United States. Prediabetes typically precedes the diagnosis of type 2 diabetes, which accounts for increased morbidity and mortality. Although the use of dietary and herbal supplements is popular worldwide, and a variety of single herbal medicines have been examined for glycemic management, the pote...
Source
#1Hiren Patel (Eli Lilly and Company)H-Index: 1
#2Kashif M. Munir (UMB: University of Maryland, Baltimore)H-Index: 8
Last. Manige Konig (Eli Lilly and Company)H-Index: 1
view all 5 authors...
Introduction The ADA-EASD consensus report recommends using glucagon-like peptide-1 receptor agonists (GLP-1RAs) as the first injectable therapy prior to basal insulin in most patients with type 2 diabetes (T2D) not at glycemic goals after oral anti-hyperglycemia medications (OH). The objective of this analysis was to assess the glycemic efficacy of once-weekly dulaglutide 1.5 mg in patients with T2D when added on a background of commonly used OH regimens.
2 CitationsSource
#1Ravi KantH-Index: 1
#2Kashif M. MunirH-Index: 8
Last. Vipin VermaH-Index: 1
view all 4 authors...
Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications
Source
#2Wedad RahmanH-Index: 1
Last. Kashif M. MunirH-Index: 8
view all 3 authors...
Source
#1Hiren PatelH-Index: 1
#2Kashif M. MunirH-Index: 8
Last. Manige KonigH-Index: 1
view all 4 authors...
Source
#1Wedad Rahman (University of Maryland Medical Center)H-Index: 1
#2Paul Joseph Solinsky (UMB: University of Maryland, Baltimore)H-Index: 1
Last. Elizabeth M. Lamos (UMB: University of Maryland, Baltimore)H-Index: 9
view all 4 authors...
ABSTRACTIntroduction: Clinicians have many safe and effective options for the treatment of type 2 diabetes that can improve glycemic control and effect other cardio-metabolic parameters. Sodium-glucose transporter-2 inhibitors (SGLT-2) are the most recent class of therapies, have a novel mechanism of action, and provide good glycemic efficacy and a favorable cardiovascular risk profile. Cost-effectiveness data can play an important role in assessing the benefits of this class of therapy in anti-...
2 CitationsSource
#1Raafia Memon (UMB: University of Maryland, Baltimore)
#2Rana Malek (UMB: University of Maryland, Baltimore)H-Index: 8
Last. Kashif M. Munir (UMB: University of Maryland, Baltimore)H-Index: 8
view all 3 authors...
Source
#2Erin D. RoeH-Index: 1
Last. Donna KingH-Index: 1
view all 8 authors...
Objective: Understanding of acromegaly disease management is hampered in the U.S. by the lack of a national registry. We describe medical management in a population with confirmed acromegaly. Methods: Inpatient and outpatient electronic health records (EHRs) were used to create a database of de-identified patients assigned the Acromegaly and Gigantism International Classification of Diseases, 9th revision (ICD-9) code and/or an appropriate pituitary procedure code at 1 of 4 regional hospital sys...
1 CitationsSource
1234